Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZNNASDAQ:BCDANASDAQ:HOTHNASDAQ:LSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$3.32-3.8%$5.31$3.06▼$135.54$2.66M-0.28433,459 shs143,226 shsBCDABioCardia$2.29+2.2%$2.22$1.63▼$4.66$11.86M0.82263,067 shs27,926 shsHOTHHoth Therapeutics$1.25+5.0%$0.89$0.58▼$3.80$16.51M0.553.66 million shs1.25 million shsLSBLakeshore Biopharma$0.96-3.9%$1.28$0.91▼$8.60$8.93M0.5920,772 shs10,127 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro-3.77%-13.32%-43.95%-44.94%-93.41%BCDABioCardia+2.23%+5.05%-19.65%-10.20%-33.24%HOTHHoth Therapeutics+5.04%+35.90%+31.22%+12.61%+25.00%LSBLakeshore Biopharma-3.90%-11.11%-15.79%-50.00%+95,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALZNAlzamend Neuro3.478 of 5 stars3.54.00.00.03.34.20.0BCDABioCardia2.9722 of 5 stars3.85.00.00.00.02.50.6HOTHHoth Therapeutics2.7272 of 5 stars3.63.00.00.01.90.81.3LSBLakeshore Biopharma0.262 of 5 stars0.03.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 3.00Buy$180.005,321.69% UpsideBCDABioCardia 3.50Strong Buy$25.00991.70% UpsideHOTHHoth Therapeutics 3.25Buy$4.00220.00% UpsideLSBLakeshore Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALZN, HOTH, LSB, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/31/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/17/2025ALZNAlzamend NeuroAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$288.00 ➝ $180.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A($3.52) per shareN/ABCDABioCardia$3K3,952.54N/AN/A($1.11) per share-2.06HOTHHoth TherapeuticsN/AN/AN/AN/A$2.03 per shareN/ALSBLakeshore Biopharma$672.27M0.01N/AN/A$8.86 per share0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$9.95MN/A0.00N/AN/AN/AN/A-289.14%7/29/2025 (Estimated)BCDABioCardia-$11.57M-$2.33N/AN/AN/A-1,999.77%N/A-208.38%8/12/2025 (Estimated)HOTHHoth Therapeutics-$7.84M-$1.14N/AN/AN/AN/A-89.68%-82.61%8/8/2025 (Estimated)LSBLakeshore Biopharma-$61.09MN/A0.00∞N/AN/AN/AN/A8/18/2025 (Estimated)Latest ALZN, HOTH, LSB, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/12/2025Q1 2025HOTHHoth Therapeutics-$0.34-$0.27+$0.07-$0.27N/AN/A3/27/2025Q4 2024HOTHHoth Therapeutics-$0.39-$0.32+$0.07-$0.32N/AN/A3/26/2025Q4 2024BCDABioCardia-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/ALSBLakeshore BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A3.803.80BCDABioCardiaN/A1.781.78HOTHHoth TherapeuticsN/A10.1710.17LSBLakeshore Biopharma0.131.170.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%BCDABioCardia20.57%HOTHHoth Therapeutics7.08%LSBLakeshore Biopharma52.64%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro30.21%BCDABioCardia20.00%HOTHHoth Therapeutics10.56%LSBLakeshore BiopharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro4801,0004.86 millionNo DataBCDABioCardia405.18 million3.67 millionOptionableHOTHHoth Therapeutics413.21 million6.18 millionNot OptionableLSBLakeshore Biopharma7739.31 millionN/AN/AALZN, HOTH, LSB, and BCDA HeadlinesRecent News About These CompaniesHead to Head Comparison: Fulcrum Therapeutics (NASDAQ:FULC) versus Lakeshore Biopharma (NASDAQ:LSB)June 10 at 1:45 AM | americanbankingnews.comLakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)April 23, 2025 | prnewswire.comLSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27thFebruary 6, 2025 | businesswire.comLakeShore Biopharma’s Financial Leap and Rabies Vaccine Trial ApprovalDecember 19, 2024 | markets.businessinsider.comLakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year GuidanceDecember 19, 2024 | prnewswire.comLakeShore Biopharma Co., Ltd: LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in ChinaDecember 13, 2024 | finanznachrichten.deLakeShore Biopharma Faces Challenges Amid Criminal Probe into Former ChairmanDecember 12, 2024 | markets.businessinsider.comLakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in ChinaDecember 12, 2024 | globenewswire.comLakeShore Biopharma Co Ltd Ordinary SharesNovember 23, 2024 | morningstar.comLakeShore Biopharma Advances PIKA Rabies Vaccine ApprovalNovember 8, 2024 | markets.businessinsider.comLakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of PakistanNovember 8, 2024 | markets.businessinsider.comLakeShore Biopharma Announces Leadership TransitionNovember 2, 2024 | markets.businessinsider.comLakeShore Biopharma Achieves Nasdaq Compliance MilestoneOctober 29, 2024 | markets.businessinsider.comLakeShore Biopharma regains ompliance with Nasdaq minimum bid price requirementOctober 29, 2024 | markets.businessinsider.comLakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 29, 2024 | prnewswire.comLakeShore Biopharma Advances with Rabies Vaccine TrialOctober 26, 2024 | markets.businessinsider.comLakeShore’s YSJA rabies vaccine receives approval for Phase III trial in ChinaOctober 26, 2024 | markets.businessinsider.comLakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies VaccineOctober 25, 2024 | prnewswire.comLakeShore Biopharma Shares Higher on Unchanged FY GuidanceOctober 10, 2024 | marketwatch.comLakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial GuidanceOctober 8, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALZN, HOTH, LSB, and BCDA Company DescriptionsAlzamend Neuro NASDAQ:ALZN$3.32 -0.13 (-3.77%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$3.62 +0.30 (+9.04%) As of 06/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.BioCardia NASDAQ:BCDA$2.29 +0.05 (+2.23%) Closing price 06/10/2025 03:59 PM EasternExtended Trading$2.30 +0.00 (+0.22%) As of 06/10/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Hoth Therapeutics NASDAQ:HOTH$1.25 +0.06 (+5.04%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$1.24 -0.01 (-1.20%) As of 06/10/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Lakeshore Biopharma NASDAQ:LSB$0.97 -0.03 (-3.10%) As of 06/10/2025 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Government Mandate Sends eVTOL Stocks Flying AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
